$COYA News

Last published 1d ago

1d agoCOYACoya Therapeutics, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
1d agoCOYACoya Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Corporate UpdateBusiness WireHOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurodegenerative disorders, announces its financial results for the quarter ended September 30, 2026 and provides a corporate update. “Completion of enrollment in our Phase 2/3 ALSTARS tr ...
2w agoCOYACoya Therapeutics to Present Neurofilament Light Chain (NfL) Biomarker Stratification Methodology in the ALSTARS Trial to Minimize the Impact of Heterogeneity in ALS Clinical Trials at the 2026 Annual NEALS MeetingBusiness WireALS (amyotrophic lateral sclerosis) is a life-threatening neurodegenerative disease characterized by a highly variable rate of progression among affected individuals The Company believes implementation of a
3w agoCOYARight Target, Small Effect? Rethinking CNS - COYA THERAPEUTICS INCEarnings Call TranscriptsOkay, we're ready to start this next session. In this one, we want to kind of continue our discussion on neurodegenerative diseases. In this session, we are going to focus on ALS. My name is Kane Akai. I'm the Director o
4w agoCOYACoya to Initiate Open-Label Extension of Phase 2/3 ALSTARS Trial of COYA 302 in ALSBusiness WireOLE planned in response to requests from ALSTARS investigators and participantsEligible participants completing 48 weeks of treatment will have the opportunity to continue receiving COYA 302Cash runway guidance remains
4w agoCOYACoya Therapeutics Announces Participation at Chardan's 10th Annual Healthcare ConferenceBusiness WireCoya Therapeutics, Inc. (NASDAQ:COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurodegenerative
1mo agoCOYACoya Therapeutics Announces Completion of Full Enrollment in Phase 2/3 ALSTARS Trial of COYA 302 for the Treatment of ALSBusiness Wire120th participant has been enrolled in ALSTARS trial achieving target enrollment Additional eligible participants already in active screening will be allowed to enroll Topline data from 24-week double-blind
1mo agoCOYACoya Therapeutics Announces Enrollment of 100th Participant in Phase 2/3 ALSTARS Trial of COYA 302 for the Treatment of ALSBusiness WireBased on current screening and enrollment rates, topline data anticipated in early Q2 2027 Additional participants continue to roll over into the active extension arm of the trial COYA 302 has received FDA Fast
2mo agoCOYACoya Therapeutics Announces Publication of Preclinical Study Demonstrating Combination Immunomodulatory Effects of COYA 303 in a Well-Established Model of Peripheral and CNS InflammationBusiness WireStudy results showed complementary immunomodulatory effects of COYA 303, a combination of proprietary low-dose IL-2 (LD-IL2) and a GLP-1 Receptor Agonist (GLP-1RA), compared to either LD-IL2 or GLP-1RA as
4mo agoCOYABEYOND THE HIT: HOW REPETITIVE HEAD TRAUMA, INFLAMMATION, AND NEURODEGENERATIVE DISEASE INTERSECT - COYA THERAPEUTICS INCEarnings Call TranscriptsGood afternoon and welcome to today's webinar. We are joined by Dr. Stanley Appeal, a leading neurologist and researcher in neurodegenerative disease at the Houston Methodist Research Institute. We're also joined by Lee
4mo agoCOYACoya Therapeutics to Present ALSTARS Trial Design at the ENCALS 2026 MeetingBusiness WireCoya Therapeutics, Inc. (NASDAQ:COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurodegenerative disorders,
4mo agoCOYACoya Therapeutics to Host Virtual Webinar on the Intersection of Repetitive Head Trauma, Brain Inflammation and Neurodegenerative DiseaseBusiness WireVirtual Live Webinar Set for Wednesday, June 24 at 4 p.m. ET / 1 p.m. PT Will be moderated by Solomon Wilcots and feature discussion and insights from CNS experts, Stanley H. Appel, M.D., Fred Grossman D.O. and
5mo agoCOYACoya Therapeutics Announces the First Cohort of Patients in the ALSTARS Trial Have Begun the Blinded Active-Treatment Extension PhaseBusiness WirePatients with ALS who have completed the 24-week, double-blind, placebo-controlled Phase of the ALSTARS Trial, have entered the 24-week blinded extension period, during which all participants receive COYA 302 Coya
5mo agoCOYACoya Therapeutics to Present ALSTARS Trial Design at the 5th ALS Drug Development SummitBusiness WireCoya Therapeutics, Inc. (NASDAQ:COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurodegenerative disorders,
6mo agoCOYACoya Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate UpdateBusiness WireCoya Therapeutics, Inc. (NASDAQ:COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurodegenerative disorders,
6mo agoCOYACoya Therapeutics Has Been Granted U.S. FDA Fast Track Designation for COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)Business WireCoya Therapeutics, Inc. (NASDAQ:COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with neurodegenerative
7mo agoCOYACoya Therapeutics Announces Publication Demonstrating Correlation Between Longitudinal Biomarker Data and Clinical Outcomes Supporting the Mechanistic Rationale for COYA 302 in Patients with ALSBusiness WireThe study evaluated serum biomarkers of lipid peroxidation, systemic inflammation, and axonal integrity in 100 randomly selected patients with ALS and included 100 healthy controls to allow for a meaningful
7mo agoCOYACoya Therapeutics Announces Planned Board Transition and Appointment of Mark H. Pavao as Independent DirectorBusiness WireHoward Berman, Ph.D., the Company's Founder and current Executive Chairman and Director, has stepped down from his roles, following the CEO transition process initiated in November 2024. Mark H. Pavao, a senior
7mo agoAVIR COYAReAlta Life Sciences Appoints Howard Berman, Ph.D., as CEO and Kia Motesharei, Ph.D., as President and COOBusiness WireAdditions Bring Extensive Capital Markets and Business Transaction Expertise to Company as it Advances Pegtarazimod into Late-Stage Clinical Trials ReAlta Life Sciences Inc., a clinical-stage biopharmaceutical company
7mo agoCOYACoya Therapeutics Announces Publication Demonstrating Regulatory T-Cell Dysfunction and Systemic Inflammation in Frontotemporal Dementia, Supporting Mechanistic Rationale for COYA 302 Immune-Restoring TherapyBusiness WireStudy results demonstrate significant reduction in regulatory T cell (Treg) function and significant increase in circulating pro-inflammatory cytokines and chemokines in patients with FTD Low-dose IL-2 plus CTLA-4 Ig
8mo agoCOYACoya Therapeutics Provides a Corporate Update and Reports Fiscal 2025 Financial ResultsBusiness WireCoya Therapeutics, Inc. (NASDAQ:COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance T-cell (Treg) function in patients with neurodegenerative disorders,
8mo agoCOYAINSIDE THE EVOLVING ALS LANDSCAPE: BIOLOGY, INNOVATION, AND CLINICAL PROGRESS - COYA THERAPEUTICS INCEarnings Call TranscriptsWelcome to COYA Therapeutics' 2026 ALS Education Webinar. I'm Dr. Fred Grossman, President and Chief Medical Officer of COYA Therapeutic, and I will be moderating the webinar. COYA is dedicated to developing combination
9mo agoCOYACoya Therapeutics to Host Webinar with Leading Medical Experts on Amyotrophic Lateral Sclerosis (ALS) Drug Development, Patient Landscape, and Ongoing Clinical TrialBusiness Wire─ Virtual Webinar on Tuesday, Feb. 17 at 3 p.m. ET / 12 p.m. PT ─ Will feature discussion and insights from Fred Grossman, D.O., FAPA; Stanley Appel, M.D.; and James Berry, M.D., MPH — accomplished physicians
9mo agoCOYACoya Therapeutics Announces $11.1 Million Private PlacementBusiness Wire- Dr. Reddy's Laboratories, Inc., a subsidiary of Coya's current strategic collaborator, makes a $10 million investment - Greenlight Capital, Coya's largest institutional shareholder, is the only other investor
10mo agoCOYACoya Therapeutics Announces U.S. FDA Acceptance of Investigational New Drug (IND) Application for COYA 302 for the Treatment of Frontotemporal Dementia (FTD)Business WireCoya Therapeutics, Inc. (NASDAQ:COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with neurodegenerative
10mo agoCOYACoya Therapeutics Receives Clinical Trial Application (CTA) Acceptance from Health Canada to Proceed with the COYA 302 ALSTARS Trial for the Treatment of Amyotrophic Lateral Sclerosis (ALS)Business WireThe CTA No Objection Letter from Health Canada allows for initiation of patient enrollment in the ALSTARS Trial at Canadian ALS centers. The ALSTARS Trial is a phase 2, placebo-controlled study that includes clinical
11mo agoCOYACoya Therapeutics Announces Patients Have Been Dosed in the ALSTARS Trial of COYA 302 for the Treatment of ALSBusiness WireThe ALSTARS Trial is a Phase 2, multi-center, randomized, double-blind, placebo-controlled study to assess the safety and efficacy of COYA 302 in patients with amyotrophic lateral sclerosis (ALS) being conducted at
11mo agoCOYACoya Therapeutics to Participate in Upcoming Investor Relations and Clinical Trials ConferencesBusiness WireCoya Therapeutics, Inc. (NASDAQ:COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with neurodegenerative
11mo agoAVIR COYAReAlta Life Sciences Appoints Dr. Howard Berman as Executive ChairmanBusiness WireReAlta Life Sciences Inc. ("ReAlta" or the "Company"), a clinical-stage biopharmaceutical company focused on safely targeting neutrophils and central components of the complement system to revolutionize the treatment of
1y agoCOYACoya Therapeutics Announces Closing of $23.0 Million Upsized Public Offering of Common Stock, Including Full Exercise of Underwriter's Option to Purchase Additional SharesBusiness WireCoya Therapeutics, Inc. (NASDAQ:COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with neurodegenerative
1y agoCOYACoya Therapeutics Announces Pricing of $20 Million Upsized Public Offering of Common StockBusiness WireCoya Therapeutics, Inc. (NASDAQ:COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with neurodegenerative
1y agoCOYACoya Therapeutics Announces Proposed Public Offering of Common StockBusiness WireCoya Therapeutics, Inc. (NASDAQ:COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company focused on developing biologics that enhance regulatory T cell (Treg) function in patients with neurodegenerative
1y agoCOYACoya Therapeutics Congratulates Scientific Advisor Dr. Shimon Sakaguchi for Receiving The Nobel Prize in Physiology or Medicine for Discovery of Regulatory T Cells and Immune FunctionBusiness WireCoya Therapeutics, Inc. (NASDAQ:COYA) congratulates our long-standing scientific advisor, Dr. Shimon Sakaguchi, on being awarded the Nobel Prize for his pioneering discovery of regulatory T cells (Tregs) which protect
1y agoCOYACoya Therapeutics Announces Completion of Patient Enrollment of an Investigator-Initiated, Open-Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Patients with Mild to Moderate Frontotemporal DementiaPR NewswireCoya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company focused on developing biologics that enhance ...
1y agoCOYACoya Therapeutics Launches the ALSTARS Trial, a Phase 2 Clinical Study to Assess the Efficacy and Safety of COYA 302 in Amyotrophic Lateral SclerosisPR NewswireCoya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company focused on developing biologics that enhance ...
1y agoCOYACoya Therapeutics' COYA 303 Shows Promising Central Nervous System (CNS) Anti-inflammatory Effects and Systemic Regulatory T Cell (Treg) Enhancing Effects in a Preclinical Animal Inflammation ModelPR NewswireCoya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance...
1y agoCOYACoya Therapeutics' COYA 302 ALS Trial Accepted by NEALS as a NEALS-Affiliated TrialPR NewswireCoya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company focused on developing biologics that enhance ...
1y agoCOYAPRISM MarketView Features Exclusive Q&A with Coya Therapeutics CEO Arun Swaminathan on Targeting Neurodegenerative Diseases Through Treg TherapiesGlobeNewswireQ&A Highlights FDA IND Clearance, Partnerships, and 2025 Milestones Across ALS and Neurodegeneration Programs NEW YORK, Sept. 03, 2025 (GLOBE NEWSWIRE) -- PRISM MarketView today published a Q&A feature with
1y agoCOYACoya Therapeutics to Participate at Upcoming September Investor ConferencesPR NewswireCoya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company focused on developing biologics that enhance ...
1y agoCOYA RDYCoya Therapeutics Announces FDA Acceptance of Investigational New Drug (IND) Application for COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)PR NewswireCoya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company focused on developing biologics that enhance ...
1y agoCOYACoya Therapeutics Reports Second Quarter Financial Results and Provides a Corporate UpdatePR NewswireCoya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company focused on developing biologics that enhance ...
1y agoCOYACoya Therapeutics to Participate in the BTIG Virtual Biotechnology Conference July 29 – 30, 2025Business WireCoya Therapeutics, Inc. (NASDAQ:COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that the management team will
1y agoCOYACoya Therapeutics to Present at the iAccess Alpha Virtual Best Ideas Summer Conference on June 24 – 25, 2025Business WireCoya Therapeutics, Inc. (NASDAQ:COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that Chief Executive Officer
1y agoCOYACoya Therapeutics Announces Issuance of New U.S. Patent Protecting Methods of Producing Recombinant Human (rh) Interleukin-2 (aldesleukin) Liquid FormulationsBusiness WirePatent protection strengthens Coya's strategic and business development optionality Coya and its partners are continuing to broaden and expand its rh IL-2 and rh IL-2 combination patent portfolio with ongoing filings
1y agoCOYACoya Therapeutics to Participate at the H.C. Wainwright 3rd Annual BioConnect Investor ConferenceBusiness WireCoya Therapeutics, Inc. (NASDAQ:COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that it will participate in
1y agoCOYACoya Therapeutics Reports First Quarter Financial Results and Provides a Corporate UpdateBusiness WireCoya Therapeutics, Inc. (NASDAQ:COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, provides a corporate update and
1y agoCOYACoya Therapeutics to Participate in Two Upcoming Conferences in May 2025Business WireCoya Therapeutics, Inc. (NASDAQ:COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that it will participate in
1y agoCOYA REPLSibylla Biotech Appoints Former Bayer CEO, Dieter Weinand, as Chairman of the Board of DirectorsGlobeNewswireMilan, Italy, May 8, 2025 – Sibylla Biotech today announced the appointment of Dieter Weinand as Chairman of its Board of Directors. Mr. Weinand is an industry veteran, boasting over 35 years in the pharmaceutical
1y agoCOYACoya Therapeutics Announces Positive Interim Results of an Investigator-Initiated Open Label Study with Low-Dose IL-2 and CTLA4-Ig Combination Treatment in Five Patients with Mild to Moderate Frontotemporal DementiaACCESS NewswireResults from the first patient cohort of an open-label proof of concept academic study with low-dose IL-2 and CTLA4-Ig demonstrated a rapid and durable statistically significant increase in the number and
1y agoCOYACoya Therapeutics Announces Publication of GLP-1/LD IL-2 Combination Biologic (COYA 303) Demonstrating Synergistic Enhancement of Regulatory T Cell Function and Protection Against Treg Apoptosis (Cell Death)Business WireCOYA 303 is an investigational biologic combination of COYA 301, Coya's low-dose interleukin 2 (LD IL-2) and a GLP-1 receptor agonist (GLP-1RA), designed to deliver a multi-targeted immunomodulatory therapeutic in